Esperion Therapeutics (ESPR) Net Income towards Common Stockholders Growth (1y) (2013 - 2026)
Esperion Therapeutics (ESPR) Net Income towards Common Stockholders Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | 36.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.48% |
| Dec 31, 2025 | 315.28% |
| Sep 30, 2025 | -2.90% |
| Jun 30, 2025 | -20.16% |
| Mar 31, 2025 | -171.30% |
| Dec 31, 2024 | 49.36% |
| Sep 30, 2024 | 26.85% |
| Jun 30, 2024 | 78.40% |
| Mar 31, 2024 | 192.46% |
| Dec 31, 2023 | -1.02% |
| Sep 30, 2023 | 23.75% |
| Jun 30, 2023 | 22.58% |
| Mar 31, 2023 | -10.41% |
| Dec 31, 2022 | 17.69% |
| Sep 30, 2022 | 19.63% |
| Jun 30, 2022 | -52.58% |
| Mar 31, 2022 | 37.27% |
| Dec 31, 2021 | 33.92% |
| Sep 30, 2021 | 18.81% |
| Jun 30, 2021 | -135.07% |